ST. LOUIS, Aug. 6, 2012 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) today announced that Gery Tomassoni M.D. FHRS has been appointed as Chief Medical Officer (CMO), effective immediately for a three-year term. Dr. Tomassoni is Director of Electrophysiology at Central Baptist Hospital in Lexington, KY. In this capacity, Dr Tomassoni will serve as the Company's clinical leader for scientific, product, clinical training and applications development. He will continue his practice in Lexington, KY and consult in his new role on a part time basis.
As an early adopter in February 2003, Dr. Tomassoni has been a long-term user of Stereotaxis technology in the treatment of complex arrhythmia. He and his team of electrophysiologists at Central Baptist Hospital were the first in the US to complete a case using the combination of Stereotaxis robotic technology with 3-D mapping technology.
"Robotics continues to be an important driver in the care and treatment of cardiac arrhythmia and I look forward to a more formalized and collaborative relationship. With Stereotaxis technology, a tremendous opportunity exists to fully transform interventional medicine," said Dr. Tomassoni.
Dr. Tomassoni received his medical degree from Pennsylvania State University, Hershey Medical College of Medicine. He completed his residency at University Hospitals of Cleveland. He then completed fellowships in Cardiovascular Medicine and Electrophysiology at Duke University Medical Center.
"We look forward to expanding our relationship with Dr. Tomassoni and embracing his insights to execute our vision focused on making robotics the standard of care for complex EP procedures. He is a highly respected leader in EP and offers a deep and valuable perspective that will greatly enhance our company," said Michael P. Kaminski, President and Chief Executive Officer of Stereotaxis.
Dr. David Burkhardt who served as the CMO for the past three years has agreed to continue his relationship in the role of Chief Development Advisor. In this capacity, Dr. Burkhardt will continue working along with Dr. Tomassoni with new product development teams focused on advancing the Epoch™ Solution robotic navigation technology platform.
"I would like to thank Dr. Burkhardt for his hard work and guidance in this capacity over the past 3 years. We are very excited to continue our relationship with him focused on leveraging this deep product knowledge to advance the product value. We are excited that respected industry leaders continue to align behind our vision for interventional medicine," continued Mr. Kaminski.
About Stereotaxis
Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. With over 100 patents for use in a hospital's interventional surgical suite, Stereotaxis helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced collaboration of life-saving information. Stereotaxis' core technologies are the Niobe® ES Remote Magnetic Navigation system, the Odyssey® portfolio of lab optimization, networking and patient information management systems and the Vdrive™ Robotic Mechanical Navigation system and consumables.
The core components of Stereotaxis systems have received regulatory clearance in the U.S., Europe, and Canada and elsewhere; the V-Loop™ circular catheter manipulator is currently under regulatory review by the U.S. Food and Drug Administration. For more information, please visit www.stereotaxis.com and www.odysseyexperience.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, our continued access to capital and financial resources on a timely basis and on terms that are acceptable, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase our systems and the timing of such purchases, the outcome of various shareholder litigation recently filed against us, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.